{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"23.2","value":"150"},{"groupId":"OG001","spread":"16.6","value":"138"},{"groupId":"OG002","spread":"66.2","value":"185"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"9"}],"units":"Participants"}],"description":"Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Clearance was estimated from population pharmacokinetic (PK) modeling. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood. Apparent oral clearence over 24 hours at steady state (ss), on Day 15 was calculated.","dispersionType":"Standard Deviation","groups":[{"description":"Single oral dose of bosutinib 400 mg on Day 1 and then bosutinib 400 mg orally once daily continuously from Day 3 up to Week 4. All participants who completed treatment in Part 1 were continued in CP2L-CML Part 2 of the study.","id":"OG000","title":"Bosutinib 400 mg (Part 1)"},{"description":"Single oral dose of bosutinib 500 mg on Day 1 and then bosutinib 500 mg orally once daily continuously from Day 3 up to Week 4. All participants who completed treatment in Part 1 were continued in CP2L-CML Part 2 of the study.","id":"OG001","title":"Bosutinib 500 mg (Part 1)"},{"description":"Single oral dose of bosutinib 600 mg on Day 1 and then bosutinib 600 mg orally once daily continuously from Day 3 up to Week 4. All participants who completed treatment in Part 1 were continued in CP2L-CML Part 2 of the study. Eleven participants who completed treatment in Part 1 were continued in CP2L-CML Part 2 of the study and 1 participant was continued in AP-CML Part 2 of the study.","id":"OG002","title":"Bosutinib 600 mg (Part 1)"}],"paramType":"MEAN","populationDescription":"Evaluable population included all enrolled participants who received at least 1 dose of study medication and had an adequate baseline efficacy assessment. 'N' (number of participants analyzed) signifies number of participants who were evaluable for this measure.","reportingStatus":"POSTED","timeFrame":"0 (pre-dose), 1, 2, 3, 4, 6, 8, 24 hours post-dose on Day 15","title":"Apparent Oral Clearance at Steady State (CL/F,ss) - Part 1","type":"PRIMARY","unitOfMeasure":"L/hr"}